PPARA and metabolic dysfunction-associated steatotic liver disease: Notably, PPAR dual agonists (that act on any two of three subtypes) and PPAR pan agonists (that act on all three subtypes) are more expected than PPAR subtype-selective (specific) agonists for treating NAFLD/NASH.